C12Y114/14001

Production of symmetrical bolaform sophorosides

The present invention relates to the field of microbial production of novel biosurfactants. More specifically, the present invention discloses the usage of a fungal strain such as the yeast Starmerella bombicola having a dysfunctional CYP52M1 cytochrome P450 monooxygenase and a dysfunctional FAO1 fatty alcohol oxidase for producing high amounts of so-called symmetrical bolaform sophorosides where both sophorose moieties are attached through a terminal glycosidic linkage to the hydrophobic linker. In addition, the present invention further discloses that the latter yeast can also be used to produce alkyl sophorosides and symmetrical bolaform glucosides.

Compositions, Systems and Methods for Atom Transfer Radical Addition Reaction

Biocatalysts and methods for performing atom transfer radical addition chemistry are described. Generally, modified metalloenzymes are utilized to perform enantioselective and/or diastereoselective atom transfer radical addition chemistry on a broad range of substrates.

RENAL SELECTIVE INHIBITION OF CYTOCHROME P450 3A5

Compositions and methods for treating hypertension in a subject are provided, including administering an antisense oligomer effective to reduce expression of cytochrome P450 3A5 (CYP3A5) enzyme. The antisense oligomer includes phosphorodiamidate morpholino oligonucleotide (PMO), phosphorothioate 2-O-methyl oligoribonucleotides (PSO), locked nucleic acid nucleotide, locked nucleic acid analog nucleotide, or another modified oligonucleotide backbone or nuclease-resistant backbone. The antisense oligomer is administered transdermally, subcutaneously, or orally, and optionally with a pharmaceutically acceptable carrier. In one embodiment, the antisense oligomer is an oligomer that is antisense to mRNAs that encode CYP3A5, for instance targeted at the AUG start site of the mRNAs that encode CYP3A5 or at a G4 structure within CYP3A5.

METHOD FOR PRODUCING FRAGRANT ALCOHOLS
20180208946 · 2018-07-26 · ·

This invention relates generally to methods and compositions for producing a sesquiterpene alcohol comprising contacting a sesquiterpene with a P450 polypeptide with monooxygenase activity.

PIGMENT FOR MEAT SUBSTITUTE COMPOSITIONS

Disclosed herein are pigment compositions for meat substitutes and meat substitutes including such pigment compositions. The pigment compositions include a thermolabile pink oyster mushroom pink chromogenic protein. The pigment compositions provide a pink and/or red color to a meat substitute composition that transitions to colorless or a brown color after cooking.

Variant Cytochrome P450 Monooxygenases and Uses Thereof

The present disclosure provides variant cytochrome P450 monooxygenase for the remediation of crude oil, PFAs, PCBs, and other organo-halides, polynucleotides encoding the variant cytochrome P450 monooxygenase, host cells expressing the variant cytochrome P450 monooxygenase, and methods of using the variant cytochrome P450 monooxygenase. Host cells can comprise the variant cytochrome P450 monooxygenase, almA (flavin binding monooxygenase), and xylE (catechol dioxygenase) for remediation of crude oil, PFAs, PCBs, and other organo-halides.

Melleolide-biosynthesis gene cluster and its applications

The present invention relates to the production of hydroxylated protoilludenes and/or sesquiterpenoid protoilludene-type aryl esters using newly identified genes that can be employed. The present invention accordingly relates to a host microorganism that has been transformed with the newly identified nucleotide sequences and to methods employing the transformed microorganism.

USE OF CYP EXPRESSION TO DIRECT THERAPEUTIC INTERVENTION IN CANCER
20180177749 · 2018-06-28 ·

Certain embodiments of the invention provide a method for identifying a cancer cell that is sensitive to a biguanide compound or other CYP epoxygenase inhibitor, comprising detecting increased expression of at least one cytochrome P450 (CYP) and/or decreased expression of soluble epoxide hydrolase (EPHX2) in the cancer cell, wherein increased CYP expression and/or decreased expression of EPHX2 in the cancer cell correlates with increased sensitivity of the cancer cell to the biguanide compound or other CYP epoxygenase inhibitor.

Enzymatic Hydroxylation of Aliphatic Hydrocarbon

The invention relates to enzymatic methods for hydroxylation in position 2 or 3 of substituted or unsubstituted, linear or branched aliphatic hydrocarbons.

MUTANT ENZYMES

This invention relates to mutant enzymes with enhanced properties and processes for oxidation of organic compound substrates using such enzymes.